PRMT5 and colorectal carcinoma: Given that PRMT5/EZH2 complex promotes CRC cell proliferation through epigenetic repression of CDKN2B, we sought to test whether combined inhibition of PRMT5 and EZH2 would exert a better therapeutic effect in CRC cells.